By: James Maitlall
The use of febuxostat (odds ratio [OR], 11.40; 95% CI, 5.10-25.43); Adherence to ULT (OR, 5.17; 95% CI, 4.89-5.47);
James Maitlall is a medical journalist who focuses on rheumatology, neurology, renal and urology topics. His work has appeared in various publications such as Rheumatology Advisor, Medical Bag, Neurology Advisor, and Renal & Urology News. James covers a range of topics including treatment options, research findings, and patient outcomes in these medical specialties.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
James Maitlall's coverage is heavily focused on medical research and health-related topics, particularly within the realm of rheumatology and related conditions. His articles frequently cite data to support their findings. When reaching out to him, consider providing access to relevant studies or data-driven insights that can contribute to ongoing discussions around treatments for rheumatoid arthritis, lupus erythematosus, ankylosing spondylitis, gout interventions, and cardiovascular risks associated with specific conditions.
Given his focus on citing data in his articles, engaging with James through fact-based contributions derived from reputable sources could effectively capture his interest. While geographic focus isn't specified for James' coverage attributes or article titles provided here, it's apparent that he concentrates more on the subject matter rather than a specific location.
This information evolves through artificial intelligence and human feedback. Improve this profile .